Global Pharmaceutical Contract Development and Manufacturing Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|全球醫藥品受託製造開發機關(CDMO)市場(2020年∼2027年) Global Pharmaceutical Contract Development and Manufacturing Market - 2020-2027|
|出版日期: 2021年05月10日||內容資訊: 英文 180 Pages||
Contract development and manufacturing organization (CDMO), also known as contract manufacturing organization (CMO), is a company that provide services to other companies in the pharmaceutical industry on a contract basis range from drug development to drug manufacturing. On the other hand, the CDMO is a combination of development and manufacturing of pharmaceutical products by different companies on a contractual basis that are constrained by a certain set of standards and rules that each company must need to adhere. In this context, all the pharmaceutical companies act as outsourcing companies that deal with the manufacturing and development of drugs that lead to improved business scalability and revenue. Also, many companies are significantly investing in these services, as it inherently provides cost-saving and time-saving benefits resulting in a maximum stake of outsourcing revenue. As such, the need for pharmaceutical contract development and manufacturing treatment is gaining significant momentum in recent years to deliver value-added services for a risk-sharing or integrated business model.
The global pharmaceutical contract development and manufacturing market size was worth US$ XX billion in 2020 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).
The growth in investments and spending on pharmaceutical research and development (R&D) coupled with the increasing pressure on healthcare providers to reduce healthcare cost is expected to propel the market growth. Furthermore, the rising demand for generics medicine and biologics to improve the therapeutic effectiveness and safety profiles for the health conditions will further enhance the demand for pharmaceutical contract development and manufacturing market globally. However, the limited outsourcing activities among well-established pharma companies' customers, along with regulatory complication associated with the drug approval are the few factors that may hamper the market growth during the forecast period. Moreover, the growing demand for cell and gene therapies is expected to fuel the penetration of the pharmaceutical contract development and manufacturing market during the forecast period.
Mounting Pressure on Pharmaceutical Providers to Reduce Healthcare Costs
As the current market trend, the healthcare sector requires to deliver improved patient care and enhance the patient's experience from the initial stage of the diagnosis till the recovery phase within or outside the healthcare organizations. Through which pharmaceutical companies are opting for pharmaceutical outsourcing services that can free an organization to concentrate on non-critical tasks and helps them to focus resources on core competencies, which further leads to the significant reduction of overall healthcare cost. As per the Insight customer call solution LTD, the appointment of BPO in the pharmaceutical and healthcare industries may lead to saving the additional cost of up to 30-60%. As such, the utility of pharmaceutical outsourcing and manufacturing activities have a prominent role in the reduction of healthcare cost.
Moreover, many automated solutions complied with complete software & skilled professionals that helps in managing efficient development of drugs and medicines, which further reduce the cost of hiring additional staff, training them and investment cost of others related resource. As a result, the inclined pressure on healthcare providers to lower healthcare cost is expected to drive the growth of the market over the forecast years.
Rapid growth in pharmaceutical products consumption in the Asia Pacific
As per the recent demographic condition, the growth in consumption of pharmaceutical products rely on the development of pharmaceutical contract development and manufacturing industry and it is rapidly increasing across the Asia Pacific region, owing to an increase in the purchasing power and growing development and consumption of novel drugs and medicines among the target audiences. The demand is also enhanced due to its improved usage in pharmaceutical outsourcing activities to meet the unmet medical needs and further replace traditional techniques and systems.
In addition, widening pharmaceutical contract development and manufacturing market opportunities is primarily driven by the surging demand for generic and speciality drugs in the Asian countries are further reinforced the product demand in the region. Pharmaceutical sector growth in the Asian economy is feasible due to growing healthcare infrastructure, increased pharmaceutical and biopharmaceutical companies, and rising target populations. Supplementary driving factors to industry growth include changing companies preferences to outsource the other critical areas to focus on the development of drugs is further promoting the consumption of pharmaceutical products, which, in turn, driving the market growth during the forecast period.
COVID-19 Impact Analysis
COVID-19 pandemic has affected the global economy in several terms, such as directly impacting the production and demand, supply chain disruption, and financial impact. With the COVID-19 disruptions in various sectors, the manufacturers' supply chain in the healthcare sector has significantly improved on a global scale to control the spread of novel coronavirus diseases. However, the ongoing pandemic further resulted in shutting down the production facilities to minimize the risk of virus spread. This has led to the implementation of lockdown policies that have a significant impact on pharmaceutical outsourcing actives throughout the world to meet high unmet medical needs among patients. Therefore, the manufacturers are keen to invest and expand their production capabilities to meet the global market's updated demand.
Despite the pandemic, there is a huge growth has been witnessed in the overall pharmaceutical products, which is expected to drive the pharmaceutical contract development and manufacturing's market size in the global market during the forecast period.
Based on the services, the pharmaceutical contract development and manufacturing market has been classified into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services.
Biologics manufacturing services segment accounted for the highest market share in the global market
In 2019, the biologics manufacturing services segment was anticipated to account for the largest share, owing to the rise in availability of biological services by numerous market players, along with growing demand for vaccine and biosimilars. Such products reduce the overall investment needed to bring a new product to market, offering access to expensive technologies, and improved flexibility are some benefits offered by CMOs, which have prompted the companies to use their biologics manufacturing services.
Moreover, the biologics manufacturing service is also expected to register significant growth in the overall market. This is due to the robust pipeline of new biological drugs due to the growing commercial success of biopharma companies across developed and developing economies is paving the growth of the biologics manufacturing services segment in the global pharmaceutical contract development and manufacturing market during the forecast period.
Based on the end-user, the pharmaceutical contract development and manufacturing market has been classified into large pharmaceutical companies, small and mid-sized pharmaceutical companies, generic pharmaceutical companies, and others.
Large pharmaceutical companies segment dominated the global pharmaceutical contract development and manufacturing market in 2019
In 2019, the large pharmaceutical companies segment dominated the pharmaceutical contract development and manufacturing market, owing to the high demand for end-to-end services from these companies, and this is the viable and efficient choice for the pharmaceutical contract development and manufacturing diagnosis. It is also expected that the large companies are also expected to grow with a significant CAGR during the forecast period, owing to they involved in precise drug development processes for pharmaceutical contract development and manufacturing industry in the forecasting period.
Based on geography, the study analyzes the pharmaceutical contract development and manufacturing market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America leads the global market throughout the forecast period
North America dominates the global pharmaceutical contract development and manufacturing market in terms of value and volume due to the rise in the number of leading pharmaceutical manufacturing companies and easy accessibility of high-quality pharmaceutical products for healthcare facilities across the region. It is also leading as a consequence of significant expansion that has been made in the U.S. healthcare industry, which, in turn, accelerating the market growth in the region. While in Europe, the rising number of clinical trials and robust growth in the generics industry are the few factors expanding the scope of the global pharmaceutical contract development and manufacturing market in the coming years.
The Asia Pacific is estimated to grow at the pharmaceutical contract development and manufacturing market's highest growth rate during the forecast period. The growth of the region is attributing to the increasing number of mergers & acquisition between Asia-based companies and other international key players, along with improving pharmaceutical facilities in the region. Also, the global companies are investing a substantial amount of funds to increase the export from the low-cost area, which is further likely to increase the pharmaceutical contract development and manufacturing diagnostic products in the domestic region during the forecast period.
The pharmaceutical contract development and manufacturing market is highly competitive, owing to the presence of big pharmaceutical brands. The key Pharmaceutical contract development and manufacturing players which are contributing to the growth of the global market include Lonza Group, Thermo Fisher Scientific Inc., Catalent, Recipharm AB, ABBVIE, Siegfried Holding AG, Evonik Industries, Boehringer Ingelheim, Piramal Pharma Limited, Fujifilm Healthcare, Asymchem Laboratories (Tianjin) Co., Ltd., WuXi AppTec, among others. The major players are adopting new product launch and expansion strategies for global growth in the Pharmaceutical contract development and manufacturing market.
Thermo Fisher Scientific
Overview: Thermo Fisher Scientific was based in Massachusetts, U.S. since 1956. The company is a significant manufacturer and provider in serving instruments and reagents concerning the life sciences area. Further, the company primarily manage an extensive base of the products in laboratory reagents and consumables, science software and services for research, analytical equipment and instruments, discovery, analysis, and manufacturing (including pharmaceutical and diagnostic products). Further, the company has 238 office locations within 48 countries around North America, Latin America, Europe, Asia-Pacific, and the Middle East countries.
Product Portfolio: The company delivers an end-to-end product offering in contract development and manufacturing that includes API, viral vector services, biologics, early and late phase development, cGMP plasmids, logistics services, clinical trial solutions, and commercial manufacturing. It further provides contract services in the areas of Bioanalytical Services, Biologics Manufacturing, Biologics Process Development, Clinical Trials, Analytical laboratory service, and more.
The global Pharmaceutical contract development and manufacturing market report would provide access to an approx. 54 market data table, 46 figures and 276 pages.
LIST NOT EXHAUSTIVE